leisure time -WSS

leisure time

author：entertainment 2025-09-07 17:24:27 - browse：9

Adam's take main illustration — Molly Ferguson/STAT

Cytokinetics was founded 26 years ago but has not yet developed a drug successfully to approval. That makes Tuesday’s Food and Drug Administration decision on its treatment for heart failure a big deal — except nearly everyone, even investors who own Cytokinetics — hopes the agency rules against it.

Hoping the FDA rejects the Cytokinetics drug, called omecamtiv mecarbil, is a relatively uncommon, up-is-down, down-is-up situation, but it makes sense in this case because the business and science of the drug are not aligned.

Consider: Cytokinetics shares rose in December when an outside group of experts convened by the FDA to examine omecamtiv’s benefits and risks recommended against the medicine’s approval. On Tuesday, the FDA is most likely to heed that advice and turn down the company’s marketing application.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Another man arrested in connection with shooting at Kansas nightclub

WSS

New Ultima Genomics DNA sequencer can read genome for $100

ARCH Venture Partners is raising $3 billion for a life sciences fund

FDA drug safety: Singulair case shows systemic surveillance flaws

Florida group launches initiative to get abortion constitutional amendment on 2024 ballot

The real point of Kenneth Smith’s execution by nitrogen gas

The PBM ad wars are taking over Washington, D.C.

Wikipedia

leisure time

focus

Medical leaders decry Supreme Court decision on affirmative action

Commercial surrogacy can be ethical, despite pope’s claims

Duchenne breakthrough therapy leaves behind pioneering families

Rare Northern Lights show in US this week: Where and how to see it

In Memoriam: Notable people who died in 2023

Congressmen charge Covid hearing ‘could have been an email’

Alkermes shareholders re

Kansas must stop changing trans people's sex listing on driver's licenses, judge says

Psychedelics group wrestles with new pharma identity

Apple Vision Pro: A first look at health apps on the new VR headset

knowledge

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

Even great ERs can’t make up for American health disparities

ARCH Venture Partners is raising $3 billion for a life sciences fund

Vertex non

Time to name cancers by genetics, not organ of origin, expert says

Rare Northern Lights show in US this week: Where and how to see it

focus

focus

explore

focus